Neos Therapeutics

Neos Therapeutics brings in $20.6M in funding for extended-release ADHD drugs

Pharmaceutical company Neos Therapeutics, Inc. announced Wednesday that it has completed a round of financing totaling $20.6 million for its late-stage pipeline of innovative extended-release (XR) products for Attention-Deficit Hyperactivity Disorder. The financing included investments by Presidio Partners, Crabtree Partners, CAC LLC, Delaware Street Capital, Burrill Life Sciences Capital Fund III and Essex Capital Corporation, […]